Andrew Gomperts, president and CEO of Hillhurst Biopharmaceuticals Inc., readily admits the San Diego-based company is "standing on the shoulders of giants" in its quest to translate the potential of five decades of research on the heme oxygenase (HO) pathway into therapeutic agents for sickle cell disease, cerebral injury and other inflammatory conditions such as multiple sclerosis.